Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Share-based Compensation (2017 - 2025)

IGC Pharma (IGC) has disclosed Share-based Compensation for 15 consecutive years, with $730000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 81.59% to $730000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.0 million, a 20.84% increase, with the full-year FY2025 number at $1.6 million, down 7.5% from a year prior.
  • Share-based Compensation was $730000.0 for Q3 2025 at IGC Pharma, up from $452000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.2 million in Q2 2022 to a low of $125000.0 in Q2 2021.
  • A 5-year average of $514210.5 and a median of $455000.0 in 2025 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 821.6% in 2022, then plummeted 69.01% in 2023.
  • IGC Pharma's Share-based Compensation stood at $523000.0 in 2021, then decreased by 7.46% to $484000.0 in 2022, then grew by 8.68% to $526000.0 in 2023, then decreased by 27.57% to $381000.0 in 2024, then skyrocketed by 91.6% to $730000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Share-based Compensation are $730000.0 (Q3 2025), $452000.0 (Q2 2025), and $455000.0 (Q1 2025).